- RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
- Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
- Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.
- PMID: 35179959
- PubMed abstract
- Source abstract
- PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions.
- Hopkins C.
- Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.
- Conference report